Harrow, Inc.
HROW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001360214
In the last 90 days, Harrow, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $912.6M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Harrow, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 96
- +17 vs. Q3 2022
- Shares held
- 18.1M
- +3.23M (+21.8%) vs. Q3 2022
- Total value
- $266.6M
- +$87.6M (+48.9%) vs. Q3 2022
- New holders
- 25
- 31 more added
- Sold out
- 8
- 22 more reduced
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HROW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 223 | $912.6M |
| Q1 2026 | 219 | $755.6M |
| Q4 2025 | 215 | $1.09B |
| Q3 2025 | 197 | $1.02B |
| Q2 2025 | 161 | $643.3M |
| Q1 2025 | 157 | $551.3M |
| Q4 2024 | 166 | $699.0M |
| Q3 2024 | 159 | $939.9M |
| Q2 2024 | 110 | $397.6M |
| Q1 2024 | 112 | $273.2M |
| Q4 2023 | 113 | $255.7M |
| Q3 2023 | 129 | $358.7M |
| Q2 2023 | 112 | $437.6M |
| Q1 2023 | 115 | $442.7M |
| Q4 2022 | 96 | $266.6M |
| Q3 2022 | 81 | $184.5M |
| Q2 2022 | 88 | $136.6M |
| Q1 2022 | 80 | $103.5M |
| Q4 2021 | 77 | $131.0M |
| Q3 2021 | 79 | $131.3M |
| Q2 2021 | 90 | $125.7M |
| Q1 2021 | 93 | $101.0M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Harrow, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −10,447−100.0% | Sold out |
| Truist Financial Corp | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,764−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −340−100.0% | Sold out |
| Invenire Partners, LP | – | – | – | – | Not filed |
| American Portfolios Advisors | – | – | – | – | Not filed |